Abstract

Giugliano RP, Desai NR, Kohli P, Rogers WJ, Somaratne R, Huang F, Liu T, Mohanavelu S, Hoffman EB, McDonald ST, Abrahamsen TE, Wasserman SM, Scott R, Sabatine MS. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study. Lancet. 2012;380:2007-2017.

The article discusses a study which examined the effects of AMG 145, a human monoclonal antibody against PCSK9, in patients with hypercholesterolaemia in a statin. The study involved patients from the U.S., Canada, Denmark, Hungary and the Czech Republic. Results showed that the antibody reduced low density lipoprotein-cholesterol (LDL-C) concentrations. Treatment-related adverse events occurred in 39 percent of the patients.

Trial: LAPLACE-TIMI 57